Tune-in today, June 12th at 2:40 p.m. ET corporate update from Corbus CEO, Yuval Cohen, Ph.D., at the 45th Annual Goldman Sachs Global Healthcare Conference: https://bit.ly/3R5a1MG
Corbus Pharmaceuticals
Pharmaceutical Manufacturing
Norwood, Massachusetts 13,589 followers
Committed to leveraging expertise in immunology to fulfill purpose of developing innovative new medicines
About us
Corbus is a precision oncology company committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus’ internal development pipeline includes CRB-701, a next generation antibody drug conjugate (ADC) that targets the expression of Nectin 4-on cancer cells to release a cytotoxic payload and CRB-601, and anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells. We are tenacious and will keep pushing the known boundaries to make breakthroughs where others have not.
- Website
-
https://www.corbuspharma.com/about/careers
External link for Corbus Pharmaceuticals
- Industry
- Pharmaceutical Manufacturing
- Company size
- 51-200 employees
- Headquarters
- Norwood, Massachusetts
- Type
- Public Company
- Founded
- 2014
- Specialties
- cancer, immunotherapy, immuno-oncology, nectin-4 biology, and integrin biology
Locations
-
Primary
Get directions
500 River Ridge Dr
Norwood, Massachusetts 02062, US
Employees at Corbus Pharmaceuticals
Updates
-
Our CEO Yuval Cohen, Ph.D. will provide a corporate update tomorrow, June 12th at 2:40 p.m. ET at the 45th Annual Goldman Sachs Global Healthcare Conference. For webcast information: https://bit.ly/3R5a1MG
-
Dr. Dominic Smethurst, Chief Medical Officer at Corbus, comments on the clinical update of SYS6002 (CRB-701), a next-generation Nectin-4 targeting antibody drug conjugate, presented at #ACO24. Read more: https://bit.ly/3wP0oLn
-
A clinical update presented at #ASCO24 showed that SYS6002 (CRB-701), a next-generation Nectin-4 targeting antibody drug conjugate, continues to demonstrate encouraging safety and efficacy observed in patients with Nectin-4 positive tumors. Learn more: https://bit.ly/3V9UTyM
-
Corbus announced today that the Poster [#296] "Clinical Update Related to the First-In-Human Trial of SYS6002 (CRB-701), A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate," has been presented at American Society of Clinical Oncology (ASCO) Annual Conference by Dr. Jian Zhang, Chief Physician (Oncology), Deputy Director of Administration, Clinical director of Phase 1 Centre, Fudan University Shanghai Cancer Center. For details: https://bit.ly/3wP0oLn #ASCO24
-
Attending #ASCO24? Updated Phase 1 clinical data for SYS-6002 (CRB-701) will be presented as a poster [#296] on Saturday, June 1st from 9 a.m. - 12 p.m. CDT. For details: https://bit.ly/4aEsN4u
-
Corbus CEO, Yuval Cohen, Ph.D., will provide a corporate update and participate in one-on-one investor meetings at the 45th Annual Goldman Sachs Global Healthcare Conference to be held June 10-13, 2024 in Miami Beach, FL. For details: [link] [PR Graphic]https://bit.ly/3R5a1MG
-
Corbus announced that the abstract [No. 3151] for a poster presentation at the 2024 American Society of Clinical Oncology (ASCO) annual meeting being held from May 31-June 4, 2024 in Chicago has been released. The ASCO abstract is titled: Clinical Update Related to the First-In-Human Trial of SYS6002 (CRB-701), A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate and will be presented as a poster [#296] on June 1, 2024 from 9:00 AM -12:00 PM CDT by Dr. Jian Zhang, Fudan University Shanghai Cancer Center. https://bit.ly/4aEsN4u #ASCO24
-
Corbus CEO, Yuval Cohen, Ph.D., spoke with BiotechTV's Brad Loncar about Corbus' pipeline, including the potential of CRB-701, a next-generation #AntibodyDrugConjugate targeting expression of Nectin-4 and the Company's development of CRB-913 for the treatment of #obesity. Watch the full interview here: https://bit.ly/3JZlRUT #RBCHealthcare
𝐑𝐁𝐂 𝐆𝐥𝐨𝐛𝐚𝐥 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞: Corbus Pharmaceuticals CEO Yuval Cohen on nectin-4 ADCs, integrin biology, and an alternative to GLPs for weight loss. Full video: https://lnkd.in/eJu6E5ha
-
Tune-in today, May 14th at 9:30 a.m. for a fireside chat with Corbus CEO, Yuval Cohen, Ph.D., at the 2024 RBC Capital Markets Global Healthcare Conference: https://bit.ly/3JTFihF #RBCHealthcare